<DOC>
	<DOC>NCT01492374</DOC>
	<brief_summary>The purpose of the study is to evaluate safety and the pharmacodynamic effects of BMS-241027 on cerebrospinal fluid (CSF) Tau, connectivity magnetic resonance imaging (MRI), and computerized cognitive tests in mild Alzheimer's disease (AD) subjects, following 9 weekly intravenous (IV) infusions of BMS-241027</brief_summary>
	<brief_title>Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Mild AD Subjects meeting National Institute of Neurological Disorders and Stroke Alzheimer's Disease Related Disorders Association(NINCDSADRDA) and Diagnostic and Statistical Manual of Mental DisordersForth Edition, Text Revision (DSMIVTR) criteria MiniMental State Exam (MMSE) Score between 20 &amp; 26 (inclusive) CSF consistent with AD pathology Screening brain MRI normal commensurate with age or demonstrate atrophy consistent with AD diagnosis (dx); reveal no more than mild white matter disease; up to 2 lacunar infarcts acceptable except in anterior thalamus, genu of internal capsule or basal forebrain; reveal no cortical infarcts; reveal no more than 4 microbleeds; reveal no focal asymmetric lobar atrophy or other findings suggesting primary cause of dementia is attributed to a cause other than AD; reveal no macrohemorrhages (&gt;10 mm) Subjects must have reliable study partners Men and Women of Non Child Bearing Potentia (WONCBP), ages 5090 years Subjects with any other medical condition other than mild AD that could explain subjects' memory or cognitive deficits Subjects diagnosed with moderate or severe AD per DSMIV criteria Subjects with a history (hx) of stroke Subjects with a hx of GI illnesses Subjects with Vitamin B12 or folate deficiency Subjects with any unstable cardiovascular (CV), pulmonary, Gastrointestinal (GI) or hepatic disease within 30 days prior to screening Subjects with active liver dx or history of hepatic intolerance Subjects with a Geriatric Depression Scale score of â‰¥ 6 at screening Subjects treated for or have had a diagnosis of schizophrenia Subjects treated for or have had a diagnosis of bipolar disease within 3 years prior to screening Subjects with a history of generalized peripheral neuropathy</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>